Literature DB >> 27234031

Improved diagnostic yield of neuromuscular disorders applying clinical exome sequencing in patients arising from a consanguineous population.

Z Fattahi1,2, Z Kalhor1, M Fadaee1,2, R Vazehan2, E Parsimehr2, A Abolhassani2, M Beheshtian1,2, G Zamani3, S Nafissi4, Y Nilipour5, M R Akbari1,6,7, K Kahrizi1, A Kariminejad2, H Najmabadi1,2.   

Abstract

Neuromuscular diseases (NMDs) include a broad range of disorders affecting muscles, nerves and neuromuscular junctions. Their overlapping phenotypes and heterogeneous genetic nature have created challenges in diagnosis which calls for the implementation of massive parallel sequencing as a candidate strategy to increase the diagnostic yield. In this study, total of 45 patients, mostly offspring of consanguineous marriages were examined using whole exome sequencing. Data analysis was performed to identify the most probable pathogenic rare variants in known NMD genes which led to identification of causal variants for 33 out of 45 patients (73.3%) in the following known genes: CAPN3, Col6A1, Col6A3, DMD, DYSF, FHL1, GJB1, ISPD, LAMA2, LMNA, PLEC1, RYR1, SGCA, SGCB, SYNE1, TNNT1 and 22 novel pathogenic variants were detected. Today, the advantage of whole exome sequencing in clinical diagnostic strategies of heterogeneous disorders is clear. In this cohort, a diagnostic yield of 73.3% was achieved which is quite high compared to the overall reported diagnostic yield of 25% to 50%. This could be explained by the consanguineous background of these patients and is another strong advantage of offering clinical exome sequencing in diagnostic laboratories, especially in populations with high rate of consanguinity.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  clinical exome sequencing; consanguineous population; diagnostic yield; neuromuscular disorders

Mesh:

Year:  2016        PMID: 27234031     DOI: 10.1111/cge.12810

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  12 in total

1.  Novel Recessive TNNT1 Congenital Core-Rod Myopathy in French Canadians.

Authors:  David Pellerin; Asli Aykanat; Benjamin Ellezam; Emily C Troiano; Jason Karamchandani; Marie-Josée Dicaire; Marc Petitclerc; Rebecca Robertson; Xavier Allard-Chamard; Denis Brunet; Chamindra G Konersman; Jean Mathieu; Jodi Warman Chardon; Vandana A Gupta; Alan H Beggs; Bernard Brais; Nicolas Chrestian
Journal:  Ann Neurol       Date:  2020-02-08       Impact factor: 10.422

2.  TNNT1 nemaline myopathy: natural history and therapeutic frontier.

Authors:  Michael D Fox; Vincent J Carson; Han-Zhong Feng; Michael W Lawlor; John T Gray; Karlla W Brigatti; J-P Jin; Kevin A Strauss
Journal:  Hum Mol Genet       Date:  2018-09-15       Impact factor: 6.150

3.  The sensitivity of exome sequencing in identifying pathogenic mutations for LGMD in the United States.

Authors:  Hemakumar M Reddy; Kyung-Ah Cho; Monkol Lek; Elicia Estrella; Elise Valkanas; Michael D Jones; Satomi Mitsuhashi; Basil T Darras; Anthony A Amato; Hart Gw Lidov; Catherine A Brownstein; David M Margulies; Timothy W Yu; Mustafa A Salih; Louis M Kunkel; Daniel G MacArthur; Peter B Kang
Journal:  J Hum Genet       Date:  2016-10-06       Impact factor: 3.172

4.  Clinical exome sequencing in 509 Middle Eastern families with suspected Mendelian diseases: The Qatari experience.

Authors:  Nader Al-Dewik; Howaida Mohd; Mariam Al-Mureikhi; Rehab Ali; Fatma Al-Mesaifri; Laila Mahmoud; Noora Shahbeck; Karen El-Akouri; Mariam Almulla; Reem Al Sulaiman; Sara Musa; Ajayeb Al-Nabet Al-Marri; Gabriele Richard; Jane Juusola; Benjamin D Solomon; Fowzan S Alkuraya; Tawfeg Ben-Omran
Journal:  Am J Med Genet A       Date:  2019-03-27       Impact factor: 2.802

5.  Mutational spectrum of autosomal recessive limb-girdle muscular dystrophies in a cohort of 112 Iranian patients and reporting of a possible founder effect.

Authors:  Marzieh Mojbafan; Reza Bahmani; Samira Dabbagh Bagheri; Zohreh Sharifi; Sirous Zeinali
Journal:  Orphanet J Rare Dis       Date:  2020-01-14       Impact factor: 4.123

6.  Genotype-guided diagnostic reassessment after exome sequencing in neuromuscular disorders: experiences with a two-step approach.

Authors:  M Krenn; M Tomschik; J Rath; H Cetin; A Grisold; G Zulehner; I Milenkovic; E Stogmann; A Zimprich; T M Strom; T Meitinger; M Wagner; F Zimprich
Journal:  Eur J Neurol       Date:  2019-08-13       Impact factor: 6.089

7.  Identification of a novel LAMA2 c.2217G > A, p.(Trp739*) mutation in a Moroccan patient with congenital muscular dystrophy: a case report.

Authors:  Youssef El Kadiri; Ilham Ratbi; Fatima Zahra Laarabi; Yamna Kriouile; Abdelaziz Sefiani; Jaber Lyahyai
Journal:  BMC Med Genomics       Date:  2021-04-21       Impact factor: 3.063

Review 8.  Facilitations and Hurdles of Genetic Testing in Neuromuscular Disorders.

Authors:  Andrea Barp; Lorena Mosca; Valeria Ada Sansone
Journal:  Diagnostics (Basel)       Date:  2021-04-14

9.  Rare Disease Diagnostics: A Single-center Experience and Lessons Learnt.

Authors:  Karin Weiss; Alina Kurolap; Tamar Paperna; Adi Mory; Maya Steinberg; Tova Hershkovitz; Nina Ekhilevitch; Hagit N Baris
Journal:  Rambam Maimonides Med J       Date:  2018-07-30

10.  Ovine congenital progressive muscular dystrophy (OCPMD) is a model of TNNT1 congenital myopathy.

Authors:  Joshua S Clayton; Elyshia L McNamara; Hayley Goullee; Stefan Conijn; Keren Muthsam; Gabrielle C Musk; David Coote; James Kijas; Alison C Testa; Rhonda L Taylor; Amanda J O'Hara; David Groth; Coen Ottenheijm; Gianina Ravenscroft; Nigel G Laing; Kristen J Nowak
Journal:  Acta Neuropathol Commun       Date:  2020-08-20       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.